The cases included refractory T lymphoblastic leukemia/lymphoma transplanted in remission after salvage chemotherapy (n = 1, day+190), CR1 FLT3-ITD + AML (n = 1, day+249), refractory/relapse AML (n = 2, day+463 and + 657), and MDS-EB1 with TP53 mutation (n = 1, day+516), high risk AML (n = 1,day+318), high risk ALL (n = 1, day+437). This evidence concerns the gene TP53 and myelodysplastic syndrome.